CLINICAL_TRIALS
research
· 2010-03-02
Clinical Trial Update: Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder [Phase 1, Phase 2]
Summary
This entry reports a completed Phase 1/2 clinical trial evaluating BMS-562086 in outpatients with major depressive disorder.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Major Depressive Disorder | Phase 1, Phase 2 | Status: COMPLETED